logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Junji Tsurutani

the innovative center of translational research and clinical science for cancer therapy
H指数:53
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

HER2CLIMB-05研究总结：曲拉妥尼（Tucatinib）对比安慰剂联合曲妥珠单抗和帕妥珠单抗用于HER2阳性转移性乳腺癌的一线维持治疗的三期研究

Targeted Oncology
IF4
2026-09-190
OAAI
Veronique Dieras; Giuseppe Curigliano; Miguel Martin; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Katarzyna J. Jerzak; Xichun Hu; Ciara C. O’Sullivan; Eriko Tokunaga; Alicia Okines; Chiun-Sheng Huang; William Jacot; Joohyuk Sohn; Eduardo Cronemberger Silva; Volkmar Mueller; Shan Yang; Giovanna Granata; Qi Shen; Erika Hamilton
Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE

曲妥珠单抗德鲁替康再次治疗在HER2阳性转移性乳腺癌中的应用：EN-SEMBLE

Breast
IF7.9
2026-08-010
PRE
Nozawa, Kazuki; Iwata, Hiroji; Mukohara, Toru; Taira, Tetsuhiko; Yoshimura, Akiyo; Nagai, Shigenori E.; Hashimoto, Jun; Matsuura, Kazuo; Mizuno, Toshiro; Shinden, Yoshiaki; Yamamoto, Mitsugu; Takano, Toshimi; Wakahara, Makoto; Terakawa, Hirofumi; Yamanaka, Takashi; Kojima, Yasuyuki; Nakayama, Takahiro; Hirakawa, Yuji; Shiosakai, Kazuhito; Tsurutani, Junji
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Datopotamab deruxtecan与化疗在先前治疗的不可手术/转移性激素受体阳性HER2阴性乳腺癌中的比较：TROPION-Breast01 III期研究的安全性和患者报告结局

ESMO Open
IF8.3
2026-07-240
OAAI
H.S. Rugo; K. Jhaveri; S. Pernas; B. Pistilli; S.-A. Im; M. De Laurentiis; S. Wang; N. Martínez Jañez; G. Borges; D.W. Cescon; M. Hattori; Y.-S. Lu; E. Hamilton; Q. Zhang; J. Tsurutani; K. Kalinsky; P.E. Rubini Liedke; Z. Nowecki; S.M. Tolaney; K. Zhao
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study☆

艾瑞布林与紫杉烷类作为HER2阳性局部晚期或转移性乳腺癌患者的一线化疗联合双HER2阻断治疗的比较：JBCRG-M06/EMERALD研究的最终生存结果☆

ESMO Open
IF8.3
2026-07-210
OAAI
S. Saji; T. Yamashita; J. Tsurutani; Y. Sagara; H. Shigematsu; T. Takano; M. Takahashi; K. Araki; N. Tamura; M. Tsuneizumi; T. Morimoto; S. Yanai; A. Kato; M. Yamaguchi; S. Kubo; Y. Hasegawa; E. Tokunaga; H. Hasegawa; S. Osaka; S. Morita
BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B)

BRCA1/2逆转突变在日本接受奥拉帕利治疗后进展的转移性乳腺癌患者中的研究：OLIVE (WJOG15321B)

Breast Cancer
IF2.9
2026-04-100
OAAI
Hitomi Sakai; Rika Kusumoto-Matsuo; Mari Hosonaga; Kazuki Nozawa; Manabu Futamura; Yuko Tanabe; Toru Mukohara; Kazuhiro Shiraishi; Tatsuya Toyama; Hiroyuki Yasojima; Noriyuki Watanabe; Hideki Sakai; Tsutomu Iwasa; Nobumichi Takeuchi; Hiroshi Tada; Kazuko Sakai; Natsuko Chiba; Toshimi Takano; Junji Tsurutani
Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B)

多基因检测（MammaPrint/Blueprint）预测激素受体阳性、HER2阴性乳腺癌早期复发的特征：一项病例对照研究（WJOG16722B）

Breast Cancer
IF2.9
2026-03-260
OAAI
Rurina Watanuki; Hitomi Sakai; Yuri Kimura; Atsushi Yoshida; Yukinori Ozaki; Akemi Kataoka; Natsue Uehiro; Atsushi Fushimi; Hidenori Kamio; Takashi Ikeno; Masashi Wakabayashi; Mayumi Iida; Tsutomu Kawaguchi; Junji Tsurutani; Toshimi Takano
Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2+ metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease

帕博利珠单抗方案在因间质性肺病停用T-DXd的HER2+转移性乳腺癌患者中的安全性与有效性

The Breast
IF0
2026-02-040
OAAI
Junji Tsurutani; Kazuki Nozawa; Toru Mukohara; Tetsuhiko Taira; Akiyo Yoshimura; Shigenori E. Nagai; Jun Hashimoto; Kazuo Matsuura; Toshiro Mizuno; Yoshiaki Shinden; Mitsugu Yamamoto; Toshimi Takano; Makoto Wakahara; Hirofumi Terakawa; Takashi Yamanaka; Yasuyuki Kojima; Takahiro Nakayama; Yuji Hirakawa; Kazuhito Shiosakai; Hiroji Iwata
Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study

奥氮平用于接受曲妥珠单抗德鲁克替康治疗的乳腺癌患者的恶心和呕吐：ERICA研究的简明语言摘要

Future Oncology
IF2.6
2025-10-240
OAAI
Hitomi Sakai; Junji Tsurutani; Yukinori Ozaki; Hiroshi Ishiguro; Kazuki Nozawa; Takashi Yamanaka; Kenjiro Aogi; Koji Matsumoto; Tsutomu Iwasa; Mariko Tokiwa; Michiko Tsuneizumi; Yasuo Miyoshi; Chiyoe Kitagawa; Mitsugu Yamamoto; Yuko Takano; Chiyo K. Imamura; Yasutaka Chiba; Daisuke Takiguchi; Takayuki Ezumi; Toshimi Takano
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康在HER2低表达转移性乳腺癌中的应用：DESTINY-Breast04随机三期试验的长期生存分析

Nature Medicine
IF50
2025-10-080
OAAI
Shanu Modi; William Jacot; Hiroji Iwata; Yeon Hee Park; Maria Vidal Losada; Wei Li; Junji Tsurutani; Naoto T. Ueno; Khalil Zaman; Aleix Prat; Konstantinos Papazisis; Hope S. Rugo; Toshinari Yamashita; Nadia Harbeck; Seock-Ah Im; Michelino De Laurentiis; Jean-Yves Pierga; Xiaojia Wang; Andrea Gombos; Eriko Tokunaga; Cecilia Orbegoso Aguilar; Lotus Yung; Feng Xiao; Yingkai Cheng; David Cameron
Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study☆

曲妥珠单抗德鲁克替康治疗后疗效及间质性肺病发生率：一项真实世界、观察性队列研究

ESMO Open
IF8.3
2025-07-250
OAAI
K. Nozawa; H. Iwata; T. Mukohara; T. Taira; A. Yoshimura; S.E. Nagai; J. Hashimoto; K. Matsuura; T. Mizuno; Y. Shinden; M. Yamamoto; T. Takano; M. Wakahara; H. Terakawa; T. Yamanaka; Y. Kojima; T. Nakayama; Y. Hirakawa; K. Kuge; A. Tanabe; J. Tsurutani
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE)
BREAST CANCER
IF2.9
2024-11-180
PRE
Nakayama, Sayuka; Yoshizawa, Ayuha; Tsurutani, Junji; Yoshimura, Kenichi; Aoki, Gaku; Iwamoto, Takayuki; Nagase, Hiroyuki; Sugimoto, Naoya; Kobayashi, Konomi; Izumi, Shinyu; Kato, Terufumi; Miyazaki, Yasunari; Kurihara, Yasuyuki; Taira, Naruto; Aihara, Tomohiko; Kikawa, Yuichiro; Mukai, Hirofumi
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) (Aug, 10.1007/s12282-024-01614-1, 2024)
BREAST CANCER
IF2.9
2024-09-200
OAAI
Nakayama, Takahiro; Niikura, Naoki; Yamanaka, Takashi; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Nomura, Hironori; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Takiguchi, Daisuke; Takata, Takehiko; Bastanfard, Armin; Shiosakai, Kazuhito; Tsurutani, Junji
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)

一项多中心、随机、双盲、安慰剂对照的研究，评估以olanzapine为基础的三联抗恶心疗法对trastuzumab deruxtecan在转移性乳腺癌患者中诱导的延迟性和持续性恶心呕吐的预防作用：ERICA研究（WJOG14320B）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Sakai, H.; Tsurutani, J.; Ozaki, Y.; Ishiguro, H.; Nozawa, K.; Yamanaka, T.; Kameoka, H.; Matsumoto, K.; Iwasa, T.; Tokiwa, M.; Tsuneizumi, M.; Miyoshi, Y.; Kitagawa, C.; Yamamoto, M.; Takano, Y.; Imamura, C. K.; Chiba, Y.; Takiguchi, D.; Ezumi, T.; Takano, T.
Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)

datopotamab deruxtecan（Dato-DXd）与研究者选择的化疗方案（ICC）在经治、不可手术/转移性HR+/HER2e乳腺癌（BC）患者中的不良事件（AEs）的暴露调整发生率（EAIRs），来自TROPION-Breast01研究。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Rugo, H. S.; Bardia, A.; Im, S-A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D.; Hattori, M.; Lu, Y-S.; Tsurutani, J.; Tolaney, S. M.; Mapiye, D.; Atuah, K.; Verma, D.; Khan, S.; Xu, B.; Pistilli, B.; Jhaveri, K.
Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04

DESTINY-Breast04研究中，曲妥珠单抗德鲁替康与医生选择治疗方案在HER2低表达、激素受体阳性转移性乳腺癌中的探索性生物标志物分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Vidal Losada, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Prat, A.; Suto, F.; Kuwahara, Y.; Boran, A. D.; Kobayashi, M.; Kumar, V.; Aguilar, C. Orbegoso; Modi, S.
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

曲妥珠单抗deruxtecan治疗脑和/或软脑膜转移的HER2-positive乳腺癌患者: 使用多中心回顾性研究 (roset-bm) 数据进行的更新的总生存分析

BREAST CANCER
IF2.9
2024-08-125
OAAI
Nakayama, Takahiro; Niikura, Naoki; Yamanaka, Takashi; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Nomura, Hironori; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Takiguchi, Daisuke; Takata, Takehiko; Bastanfard, Armin; Shiosakai, Kazuhito; Tsurutani, Junji

研究方向

暂未获取到该数据
K
Kazuhiko Nakagawa
H 指数:103论文数:1,451被引数:6.1万
T
Toshimi Takano
H 指数:36论文数:394被引数:8,015
T
Tsutomu Iwasa
H 指数:28论文数:165被引数:4,093
M
Masato Takahashi
H 指数:62论文数:560被引数:3.6万
S
Shanu Modi
H 指数:60论文数:418被引数:1.9万
H
Hiroji Iwata
H 指数:89论文数:843被引数:5.6万
J
Joohyuk Sohn
H 指数:59论文数:635被引数:2.7万
N
Naoki Niikura
H 指数:34论文数:263被引数:9,026
T
Takashi Yamanaka
H 指数:27论文数:288被引数:3,261
S
Seock‐Ah Im
H 指数:98论文数:1,144被引数:6.8万